Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dose-Response in HRPC Bone Metastases
NCT00667199Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2005
- Primary completion
- Apr 2008
- Modality
- Radiopharmaceutical
01
Overview
Phase 2, randomised, double-blind trial of radium-223 dichloride in prostate cancer (PCa) (4 arms), sponsored by Bayer. Primary endpoints: Pain Assessment using Visual Analogue Scale at 16 weeks and Analgesic Consumption at 16 weeks. Started May 2005; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00667199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667199.